Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

Bellentani, 2017, The epidemiology of non-alcoholic fatty liver disease, Liver Int, 37, 81, 10.1111/liv.13299 Younossi, 2016, The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe, Hepatology, 64, 1577, 10.1002/hep.28785 Ampuero, 2012, Influence of non-alcoholic fatty liver disease on cardiovascular disease, Gastroenterol Hepatol, 35, 585, 10.1016/j.gastrohep.2012.02.005 Ampuero, 2015, Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis, Rev Esp Enfermedades Dig, 107, 10 Musso, 2016, Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities, Diabetes Care, 39, 1830, 10.2337/dc15-1182 Kim, 2018, Association between non-alcoholic fatty liver disease and cancer incidence rate, J Hepatol, 68, 140, 10.1016/j.jhep.2017.09.012 Hagström, 2017, Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD, J Hepatol, 67, 1265, 10.1016/j.jhep.2017.07.027 Ampuero, 2018, The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity, Aliment Pharmacol Ther, 48, 1260, 10.1111/apt.15015 Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 McPherson, 2010, Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease, Gut, 59, 1265, 10.1136/gut.2010.216077 McPherson, 2017, Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis, Am J Gastroenterol, 112, 10.1038/ajg.2016.453 Ooi, 2017, Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese, Obes Surg, 27, 115, 10.1007/s11695-016-2246-5 Vilar-Gomez, 2018, Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers, J Hepatol, 68, 305, 10.1016/j.jhep.2017.11.013 Shah, 2009, Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 7, 1104, 10.1016/j.cgh.2009.05.033 Bedossa, 2014, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease, Hepatology, 60, 565, 10.1002/hep.27173 Finazzi, 2011, Calibration belt for quality-of-care assessment based on dichotomous outcomes, PLoS One, 6, 10.1371/journal.pone.0016110 Hilden, 1996, Regret graphs, diagnostic uncertainty and Youden’s Index, Stat Med, 15, 969, 10.1002/(SICI)1097-0258(19960530)15:10<969::AID-SIM211>3.0.CO;2-9 Vickers, 2006, Decision curve analysis: a novel method for evaluating prediction models, Med Decis Mak, 26, 565, 10.1177/0272989X06295361 Pencina, 2008, Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond, Stat Med, 27, 157, 10.1002/sim.2929 Xiao, 2017, Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis, Hepatology, 66, 1486, 10.1002/hep.29302 Sterling, 2006, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, 43, 1317, 10.1002/hep.21178 Petta, 2017, Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD, Aliment Pharmacol Ther, 46, 617, 10.1111/apt.14219 Castera, 2018, Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough, Liver Int, 38, 67, 10.1111/liv.13658 Ampuero, 2018, Editorial: looking for patients at risk of cirrhosis in the general population-many needles in a haystack, Aliment Pharmacol Ther, 47, 692, 10.1111/apt.14517 Bertot, 2018, Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease, Liver Int, 38, 1793, 10.1111/liv.13739 Vickers, 2008, Decision analysis for the evaluation of diagnostic tests, prediction models, and molecular markers, Am Stat, 62, 314, 10.1198/000313008X370302 2016, EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, J Hepatol, 64, 1388, 10.1016/j.jhep.2015.11.004